CLINICAL RESEARCH POSTER PRESENTATION ABSTRACTS
Please note: All posters will be displayed in
Salons 10-12.
THURSDAY, 10:15-11:00 AM
Huber R, Ditfurth A, Amann F, Kümmerer K, Rostock
M, Trittler R, Merfort I.
Tormentill for active ulcerative colitis—a pilot
study.
Center for Complementary Medicine roman.huber@uniklinik-freiburg.de
BACKGROUND: Extracts from Tormentillae rhizoma
(TR) have anti-inflammatory and anti-secretory effects. Because of promising
effects in single patients with ulcerative colitis (UC) we investigated
tolerability, safety and effectivity in patients with this disease.
METHODS: 16 patients with active UC (clinical
activity index (CAI) ³5) were included and received TR subsequently
in the doses 1200, 1800, 2400 and 3000mg per day for three weeks respectively.
Each therapy phase was followed by a phase without therapy. Outcome
parameters were tolerability, side effects, CAI and C-reactive protein
(CRP).
RESULTS: Tolerability of all doses was rated
as good. Discomfort in the upper abdomen occurred in 8 patients (50%)
but was only mild and did not require discontinuation of the medication.
Safety parameters remained unchanged. Mean CAI and CRP improved from
8.3±2.8 and 13.0±14.3 at baseline to 3.9±2.6 and 8.3±13.5 during intake
of 2400mg TR per day. During therapy 11 patients (69%) came into a complete
remission (CAI ²4). In each phase without therapy the CAI deteriorated.
3000mg had no additional effect. Concomitant medication with aminosalicylates
was unchanged and steroids could be reduced during the study.
CONCLUSION: TR is a safe and promising new option
for the treatment of active UC, which should be evaluated in a controlled
study.
Back